Norepinephrine
| Evidence Level: L4 | Predicted Indications: 3 |
Table of Contents
Norepinephrine: Obstructive lung disease
One-Sentence Summary
Norepinephrine is an injectable adrenergic drug whose original indications include hypotensive disorder, asthma, bronchitis, emphysema and bronchiectasis. The TxGNN model predicts it may be effective for obstructive lung disease, but the support is thin: 1 loosely related clinical trial and about 20 publications, mostly reviews and physiology studies.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not recorded in the local data |
| Predicted New Indication | Obstructive lung disease |
| TxGNN Prediction Score | 0.9984 |
| Evidence Level | L4 |
| Canada Market Status | Marketed (marketed DINs: 5 of 6; dormant: 1) |
| Number of DINs | 6 (marketed: 5) |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available. Based on general pharmacology, norepinephrine acts on adrenergic receptors (mainly alpha-adrenergic, with some beta effects) and is a potent vasopressor. The reviews retrieved describe adrenergic signalling and sympathetic innervation as part of how airway tone and inflammation are regulated in asthma and COPD, which gives a plausible but indirect biological link.
The predicted indication is also close to the drug’s original indications. Asthma, bronchitis, emphysema and bronchiectasis are all obstructive airway conditions, so this is nearer to an on-label-adjacent use than a true repurposing.
The benefit-risk balance is the main concern. Systemic norepinephrine is a strong vasoconstrictor, and non-selective use for airway disease carries risks of hypertension, arrhythmia and tissue ischaemia. A favourable profile for this use has not been established.
Clinical Trial Evidence
| Trial Number | Phase | Status | Enrollment | Key Findings |
|---|---|---|---|---|
| NCT02966665 | Phase 1 | Recruiting | 420 | Study of vascular function, hypertension rehabilitation and exercise/skeletal muscle feedback. It does not test norepinephrine for obstructive lung disease and provides no efficacy or safety evidence for this indication (relevance grade C). |
Literature Evidence
None of the publications below is a clinical trial of norepinephrine in obstructive lung disease. Most are narrative reviews or physiology studies.
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 29696025 | 2018 | Review | Front Immunol | Adrenergic signalling at the interface of allergic asthma and viral infections |
| 21271508 | 2011 | Review | Pneumologie | Airway innervation in asthma and COPD, including norepinephrine from sympathetic fibres |
| 41601146 | 2026 | Review | Ann Med | Neuroimmune circuits in respiratory disease and therapeutic targeting |
| 24486056 | 2014 | Review | Semin Immunol | Neuroendocrine regulation of inflammation |
| 3332227 | 1987 | Review | Crit Care Clin | Catecholamines (norepinephrine, epinephrine, dopamine) in critical care |
| 40870471 | 2025 | Review | Medicina (Kaunas) | Anxiety and depression as comorbidities of COPD |
| 19175913 | 2009 | Preclinical | Respir Res | Mouse model of emphysema with systemic manifestations |
| 3966494 | 1985 | Physiology study | Am J Med | Effect of hypoxaemia on sodium and water excretion in advanced chronic obstructive lung disease |
| 29030339 | 2018 | Physiology study | Am J Physiol Heart Circ Physiol | Muscle alpha-adrenergic responsiveness during exercise in COPD patients |
| 11099681 | 2000 | Clinical study | Am J Med | Mechanisms of hypertension in COPD with acute respiratory failure, including norepinephrine levels |
Canada Market Information
| DIN | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| 02501449 | Norepinephrine Bitartrate in 5% Dextrose Injection | Injection | Not available |
| 02501430 | Norepinephrine Bitartrate in 5% Dextrose Injection | Injection | Not available |
| 00893285 | Norepinephrine Bitartrate Injection USP | Injection | Not available |
| 02485680 | Norepinephrine Bitartrate Injection USP | Injection | Not available |
| 02358743 | Norepinephrine Bitartrate Injection, USP | Injection | Not available |
A sixth authorization (DIN 02540630, Norepinephrine Bitartrate Injection) is also valid. All six are single-ingredient products with valid status.
Safety Considerations
- Contraindications suggested by the knowledge graph (not label text): hypertensive disorder, hypertension and thrombotic disease.
- Drug Interactions: 70 interactions were identified in total, all of the 20 listed being Moderate. The main groups are:
- Antidiabetic drugs: acarbose, metformin, pioglitazone, repaglinide, chlorpropamide, and the DPP-4 inhibitors (sitagliptin, saxagliptin, linagliptin, alogliptin).
- SGLT2 inhibitors: canagliflozin, dapagliflozin, empagliflozin.
- GLP-1 agonists: semaglutide, dulaglutide, albiglutide.
- Insulins: aspart, degludec, detemir.
- Sympathomimetic anorectics: phentermine, diethylpropion.
- Systemic use may cause hypertension, arrhythmia and tissue ischaemia, as noted in the mechanistic assessment.
Please refer to the package insert for full warnings and contraindications.
Conclusion and Next Steps
Decision: Hold
Rationale: The TxGNN score is very high, but no clinical study tests norepinephrine for obstructive lung disease. The only registered trial is unrelated, and the literature consists of indirect reviews and physiology studies. The cardiovascular risks of systemic use also mean a favourable benefit-risk profile is not established.
To proceed, the following is needed:
- Package insert warnings and contraindications from Health Canada, plus the approved indication text for each DIN
- Detailed mechanism of action data
- Clinical evidence (at least a well-designed Phase 2 study) showing benefit in obstructive airway disease
- A safety and route assessment for non-vasopressor, airway-targeted use, including cardiovascular risk mitigation
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.